- MedPharm has signed an agreement with a global pharmaceutical company to support the commercial site transfer and manufacturing of a branded specialty topical pharmaceutical product.
- The agreement will generate technology transfer revenues in 2026 and 2027, followed by commercial manufacturing revenues in 2027.
MedPharm, a contract drug development and manufacturing organization focused on topical and transdermal products, has signed an agreement with a global pharmaceutical company to support the commercial site transfer and manufacturing of a branded specialty topical pharmaceutical product.
The agreement marks MedPharm’s fifth commercial deal in the past 20 months and expands its portfolio of pharmaceutical partnerships and commercial programs at its manufacturing site in Durham, North Carolina. The company will provide technical transfer services to support commercial production of the product.
MedPharm has nearly three decades of experience in the development and manufacturing of topical, transdermal and transepithelial drug products. The company will use this expertise to support the transfer of the product to its Durham manufacturing site and subsequent commercial production.
“We are very pleased to finalize yet another important deal this year, in this instance supporting a cornerstone client who is moving a branded specialty pharmaceutical product to our site. MedPharm will work with its partner to support the successful transfer of the product.”
Bill Humphries, Chief Executive Officer of MedPharm
The agreement is expected to contribute technology transfer revenues to MedPharm in 2026 and 2027, with commercial manufacturing revenues expected in 2027.
